CKLIFE SCIENCES (00775) rose over 8% again, gaining 8.6% to HK$1.01 by the time of writing, with a turnover of HK$23.28 million. The company presented its tumor growth inhibition research achievements at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. Key highlights included significant progress in developing cancer vaccines targeting trophoblast cell surface antigen 2 (TROP2), preferentially expressed antigen in melanoma (PRAME), and programmed death-ligand 1 (PD-L1), demonstrating potential in suppressing tumor growth. Dr. To Kin Ming, Vice President and Scientific Director of CKLIFE SCIENCES, stated that the encouraging results of the company’s TROP2 and PRAME/PD-L1 cancer vaccine candidates are expected to accelerate the development of effective therapeutic cancer vaccines. The current goal is to advance these candidates to clinical trial stages.